Last reviewed · How we verify

Ciprofloxacin HCl and Hydrocortisone

Farmoquimica S.A. · Phase 3 active Small molecule

Ciprofloxacin HCl and Hydrocortisone is a Fluoroquinolone antibiotic + corticosteroid combination Small molecule drug developed by Farmoquimica S.A.. It is currently in Phase 3 development for Acute otitis externa (swimmer's ear), Otitis media with effusion or tympanostomy tubes. Also known as: Otociriax.

Ciprofloxacin kills bacteria by inhibiting DNA gyrase and topoisomerase IV, while hydrocortisone reduces inflammation and immune response in the ear.

Ciprofloxacin kills bacteria by inhibiting DNA gyrase and topoisomerase IV, while hydrocortisone reduces inflammation and immune response in the ear. Used for Acute otitis externa (swimmer's ear), Otitis media with effusion or tympanostomy tubes.

At a glance

Generic nameCiprofloxacin HCl and Hydrocortisone
Also known asOtociriax
SponsorFarmoquimica S.A.
Drug classFluoroquinolone antibiotic + corticosteroid combination
TargetBacterial DNA gyrase and topoisomerase IV; glucocorticoid receptor
ModalitySmall molecule
Therapeutic areaOtology / Infectious Disease
PhasePhase 3

Mechanism of action

This is a fixed-dose combination designed for otic (ear) use. Ciprofloxacin is a fluoroquinolone antibiotic that prevents bacterial DNA replication by inhibiting essential enzymes. Hydrocortisone is a corticosteroid that suppresses local inflammation and immune-mediated tissue damage, reducing pain and swelling associated with ear infections.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Ciprofloxacin HCl and Hydrocortisone

What is Ciprofloxacin HCl and Hydrocortisone?

Ciprofloxacin HCl and Hydrocortisone is a Fluoroquinolone antibiotic + corticosteroid combination drug developed by Farmoquimica S.A., indicated for Acute otitis externa (swimmer's ear), Otitis media with effusion or tympanostomy tubes.

How does Ciprofloxacin HCl and Hydrocortisone work?

Ciprofloxacin kills bacteria by inhibiting DNA gyrase and topoisomerase IV, while hydrocortisone reduces inflammation and immune response in the ear.

What is Ciprofloxacin HCl and Hydrocortisone used for?

Ciprofloxacin HCl and Hydrocortisone is indicated for Acute otitis externa (swimmer's ear), Otitis media with effusion or tympanostomy tubes.

Who makes Ciprofloxacin HCl and Hydrocortisone?

Ciprofloxacin HCl and Hydrocortisone is developed by Farmoquimica S.A. (see full Farmoquimica S.A. pipeline at /company/farmoquimica-s-a).

Is Ciprofloxacin HCl and Hydrocortisone also known as anything else?

Ciprofloxacin HCl and Hydrocortisone is also known as Otociriax.

What drug class is Ciprofloxacin HCl and Hydrocortisone in?

Ciprofloxacin HCl and Hydrocortisone belongs to the Fluoroquinolone antibiotic + corticosteroid combination class. See all Fluoroquinolone antibiotic + corticosteroid combination drugs at /class/fluoroquinolone-antibiotic-corticosteroid-combination.

What development phase is Ciprofloxacin HCl and Hydrocortisone in?

Ciprofloxacin HCl and Hydrocortisone is in Phase 3.

What are the side effects of Ciprofloxacin HCl and Hydrocortisone?

Common side effects of Ciprofloxacin HCl and Hydrocortisone include Ear irritation or discomfort, Pruritus, Headache, Taste perversion.

What does Ciprofloxacin HCl and Hydrocortisone target?

Ciprofloxacin HCl and Hydrocortisone targets Bacterial DNA gyrase and topoisomerase IV; glucocorticoid receptor and is a Fluoroquinolone antibiotic + corticosteroid combination.

Related